AGHeadlines April 2025 - Women's health UK

AGHeadlines brings you updates every 3 months on WID-easy, AmniSure, PartoSure, Dilapan-S, Lumella, Neotech, and DandleLION to help you achieve the best possible outcomes by staying informed of the latest developments and resources.

What’s in this edition?

WID-easy Makes Headlines
New Study Compares IOL Methods
Upcoming Events
New Southern Account Manager
Coming Soon: Carevix ™

WID-EASY ON TV & IN THE NEWS

The launch of the WID-easy test for endometrial cancer has made headlines across the UK. With broadcast features on Channel 5, ITV news, and This Morning, and printed in national publications like The Guardian, The Times, and The Telegraph - the groundbreaking swab test offers a more accurate, less invasive, more accessible alternative to traditional triage methods for women with abnormal uterine bleeding.

With the potential to spare thousands of women from unnecessary invasive procedures, the WID-easy simple test for endometrial cancer is set to transform gynaecological care in the UK.

Find out more about the WID-easy test here.

NEW EVIDENCE AND DATA

DILAPAN-S 99% Probability of Reducing Risk of C-Section for Multiparous Women

Meta-analysis of RCT data on 1,731 women
Aimed to compare the cesarean delivery rate of DILAPAN-S to misoprostol, dinoprostone vaginal insert, and Foley Balloon
Overall cesarean delivery rates: No significant difference observed between DILAPAN-S (28%) and other methods (30%).
Subgroup benefit for multiparous women: Subgroup analysis demonstrated significant interaction with parity with a 99% probability of lowering risk of cesarean rates among multiparous women induced with Dilapan-S.
Safety profile: Maternal and neonatal outcomes were similar between DILAPAN-S and other methods, except a significantly lower rate of complications during ripening (19% vs 47%) in DILAPAN-S group.
Patient satisfaction: DILAPAN-S group showed significantly higher patient satisfaction during cervical ripening and less pain while the drug/device was in place.

Find out more about DILAPAN-S here.

UPCOMING EVENTS

AGHealth will be present at:

MMF Midlands 20th March - Birmingham
RCOG World Congress 23rd-25th June - London

Webinars - click to register:

NEW DILAPAN-S - May 17th @ 12noon - Drop-in Session
DandleLION - May 27th @ 11:30am - Neonatal Positioning Masterclass
DILAPAN-S - May 30th @ 12noon - Virtual Training
AmniSure - June date TBC - Webinar

NEW SOUTHERN ACCOUNT MANAGER

We are excited to introduce Chris Kelly, the our newest team member and account manager for the South of the UK. Chris brings over 20 years of extensive healthcare experience, a deep passion for science, and a relentless drive to make a meaningful impact. A dedicated father of three boys, he balances professional expertise with a personal understanding of care and commitment. Chris combines knowledge, experience, and a genuine desire to drive positive change in healthcare.

COMING SOON TO THE UK: CAREVIX™

We are thrilled to announce the upcoming UK launch of Carevix, the atraumatic cervical stabiliser engineered with vacuum technology proven to reduce pain during transcervical procedures.

Gentle: Significantly reduces pain and bleeding during cervical engagement while delivering robust traction and manoeuvrability 1
Intuitive: Engineered for ease of use and to mimic current clinical practice requiring minimal learning curve
Versatile: Designed to be used in various transcervical procedures

Book a meeting with someone from our team to find out more about Carevix.

References:

1) Yaron, M., et al. An Innovative Atraumatic Uterine Cervical Traction Device: A Randomized Trial. Poster presented at: European Society of Contraception and Reproductive Health. Ghent - Belgium, May 2022.